MEND Biotechnology Development

MEND Biotechnology Development applies advanced formulations and alternate route of administration technologies to improve overall sustainability and "developability." We generate fully-integrated development plans to ensure a "clear line of site" from research to commercialization. We work with our own proprietary platform, as well as conduct feasibility and preclinical studies for others’ licensed intellectual property.

Procedure

Our core capabilities are:

  • Analytics
  • Aerosol Engineering
  • Assay Development
  • Bioinformatics
  • Cell culture and Expression Systems
  • Dessication Systems
  • Drug Delivery System Design
  • Extraction/Purification
  • Formulation Development
  • Nanoparticle Engineering
  • Nucleic Acid Design and Synthesis
  • Polymer Chemistry
  • Protein Chemistry
  • Stability Testing
  • Validation

MEND Biotechnology Development’s two primary development programs include inhaled capreomycin powder in phase II clinical testing, and inhaled BCG vaccine in pre-clinical testing. View our Pipeline.